4.4 Article

Quantification of benzodiazepines in whole blood and serum

Journal

INTERNATIONAL JOURNAL OF LEGAL MEDICINE
Volume 120, Issue 6, Pages 323-330

Publisher

SPRINGER
DOI: 10.1007/s00414-005-0042-1

Keywords

benzodiazepines; whole blood; LC-MS; HPLC-PDA; measurement uncertainty

Ask authors/readers for more resources

A high-performance liquid chromatography method for the determination of benzodiazepines and their metabolites in whole blood and serum using mass spectrometry (MS) and photodiode array (PDA) detection is presented. The combination of both detection types can complement each other and provides extensive case relevant data. The limits of quantification (LOQ) with the MS detection lie between 2 and 3 mu g/l for the following benzodiazepines or metabolites: 7-amino-flunitrazepam, alprazolam, desalkyl-flurazepam, desmethyl-flunitrazepam, diazepam, flunitrazepam, flurazepam, alpha-hydroxy-midazolam, lorazepam, midazolam, nitrazepam, nordazepam and oxazepam, respectively 5 mu g/l for lormetazepam and 6 mu g/l for bromazepam. The LOQ of clobazam determined with the PDA detector is 10 mu g/l. A convenient approach for determining the measurement uncertainty of the presented method-applicable also for other methods in an accreditation process-is presented. At low concentrations (< 10 mu g/l), measurement uncertainty was estimated to be about 50%, and at concentrations > 180 mu g/l, it was estimated to be about 15%. One hundred and twenty-eight case data acquired over 1 year are summarised.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available